APA (7th ed.) Citation

Sborov, D. W., Canella, A., Hade, E. M., Mo, X., Khountham, S., Wang, J., . . . Pichiorri, F. (2017). A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia & Lymphoma, 58(10), 2310. https://doi.org/10.1080/10428194.2017.1298751

Chicago Style (17th ed.) Citation

Sborov, Douglas W., et al. "A Phase 1 Trial of the HDAC Inhibitor AR-42 in Patients with Multiple Myeloma and T- and B-cell Lymphomas." Leukemia & Lymphoma 58, no. 10 (2017): 2310. https://doi.org/10.1080/10428194.2017.1298751.

MLA (9th ed.) Citation

Sborov, Douglas W., et al. "A Phase 1 Trial of the HDAC Inhibitor AR-42 in Patients with Multiple Myeloma and T- and B-cell Lymphomas." Leukemia & Lymphoma, vol. 58, no. 10, 2017, p. 2310, https://doi.org/10.1080/10428194.2017.1298751.